The Chennai based Tablets India Ltd.(TIL), the pioneer in amino acid based drugs in the country and a leading formulation manufacturer, has launched a probiotic drug in the market, developed through its tie-up with the Japanese based probiotic drug major, TOA Pharmaceutical Co. Ltd.
Talking to Pharmabiz.com, R.K.Jhaver, President & Chief Executive of TIL said the new probiotic drug 'Bifilac' has properties to correct antibiotic-induced diarrhea and restore 'the inner rain forests' of the human gastro-intestinal eco system. Bifilac stimulates intestinal immunity and can correct a host of gastrointestinal problems like constipation, diarrhea, irritable bowel syndrome, mouth ulcers, and so on, if taken regularly.
The unique feature of Bifilac unlike common probiotics, is that it works at different levels of the human digestive tract through raising the counts of Lactobacillus in the small intestines and bifidobacterial counts in the colon. This special probiotic is available in capsules and sachets for oral use in adults and children. TIL would manufacture and market the drugs in the domestic market and overseas markets where TOA Pharma is not operating.
Jhaver further explained, "Normally, when antibiotics are administered, the good bacteria useful to the body also die along with harmful bacteria. This wholesale destruction of the gastro-intestinal ecology causes numerous health problems which can be corrected by the regular intake of Bifilac."